Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.03 USD | +0.86% | -7.09% | +72.57% |
Evolution of the average Target Price on Iovance Biotherapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Iovance Biotherapeutics, Inc.
Piper Sandler | |
Wells Fargo Securities | |
Barclays | |
Goldman Sachs | |
Chardan Research | |
HC Wainwright | |
Stifel Nicolaus | |
Baird | |
Oppenheimer | |
Truist Securities | |
JMP Securities | |
Guggenheim | |
Chardan | |
Jefferies & Co. |
EPS Revisions
- Stock
- Equities
- Stock Iovance Biotherapeutics, Inc. - Nasdaq
- Consensus Iovance Biotherapeutics, Inc.